ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.801,19
0,65%
S&P 500
5.214,08
0,51%
Dow Jones
39.387,76
0,85%
Euro vs US Dollar
1,07779
-0,03%
Bitcoin
63.028,84
-0,03%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Prelude Therapeutics Inc (PRLD)

  7. Prelude Therapeutics Inc (PRLD) News

PRLD

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PRLD
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202413h01GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
09/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413h01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
06/05/202422h24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/04/202422h35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202422h45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202400h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202400h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202400h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202400h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202423h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
29/02/202422h05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202423h22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
15/02/202422h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202422h05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/02/202422h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
08/01/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202315h34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202315h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h37Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h05Business WirePrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h05GlobeNewswire Inc.Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
14/10/202318h30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
06/10/202315h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
29/08/202314h30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberNASDAQ:PRLDPrelude Therapeutics Inc
03/08/202314h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PRLD

Kürzlich von Ihnen besucht

NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
FX
EURJPY
Euro vs Yen
CCOM
US100
US Tech 100
COIN
BTCUSD
Bitcoin
AMEX
XLE
Energy Select Sector SPDR
USOTC
BASFY
BASF (QX)
USOTC
BNPQY
BNP Paribas (QX)
TG
432
Arbor Metals
NYSE
KO
Coca Cola
AMEX
XLV
Health Care Select Sector
TG
ALV
Allianz
DBI
DAX
DAX
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten